Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year
Filters applied: . Clear all
Page 1
A Randomized, Placebo-controlled, Clinical Trial of Prazosin for the Treatment of Alcohol Use Disorder.
Wilcox CE, Tonigan JS, Bogenschutz MP, Clifford J, Bigelow R, Simpson T. Wilcox CE, et al. J Addict Med. 2018 Sep/Oct;12(5):339-345. doi: 10.1097/ADM.0000000000000413. J Addict Med. 2018. PMID: 29664896 Free PMC article. Clinical Trial.
OBJECTIVES: The noradrenergic system plays an important role in the pathophysiology of alcohol use disorder (AUD). Medications in this class may reduce drinking. ...METHODS: Thirty-six individuals with AUD were randomized to treatment with pr
OBJECTIVES: The noradrenergic system plays an important role in the pathophysiology of alcohol use disorder (AUD). Medi …
Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial.
Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM, Leggio L. Kenna GA, et al. Addict Biol. 2016 Jul;21(4):904-14. doi: 10.1111/adb.12275. Epub 2015 Jun 2. Addict Biol. 2016. PMID: 26037245 Free PMC article. Clinical Trial.
Evidence suggests that the norepinephrine system represents an important treatment target for alcohol dependence (AD) and the α1 -blocker prazosin may reduce alcohol drinking in rodents and alcoholic patients. ...A double-blind placebo-contro
Evidence suggests that the norepinephrine system represents an important treatment target for alcohol dependence (AD) and the …
Feedback